dc.contributor.author | Salamonsen, Anita | |
dc.contributor.author | Drageset, Brit Johanne | |
dc.contributor.author | Fønnebø, Vinjar | |
dc.date.accessioned | 2017-01-03T12:38:26Z | |
dc.date.available | 2017-01-03T12:38:26Z | |
dc.date.issued | 2012-03 | |
dc.description.abstract | Chronically ill people are frequent
users of complementary and alternative
medicine (CAM). Some
patients experience great benefits
from their use of CAM, like patient
“XX” in this case report. XX was
diagnosed with secondary progressive
multiple sclerosis in 2004 and
has reported a “best case” after the
use of Dr Birgitta Brunes’ unconventional
treatment. The patient
reports that many of her symptoms
that, according to her neurologist,
were irreversible are gone or have
been greatly reduced. Such patientdefined
“best cases” related to the
use of CAM should be further
explored to optimize and safeguard
patients’ treatment decisions and
treatment outcomes. | en_US |
dc.identifier.citation | Global Advances in Health and Medicine 2012, 1(1):30-32 | en_US |
dc.identifier.cristinID | FRIDAID 916456 | |
dc.identifier.issn | 2164-9561 | |
dc.identifier.issn | 2164-957X | |
dc.identifier.uri | https://hdl.handle.net/10037/10090 | |
dc.identifier.urn | URN:NBN:no-uit_munin_9238 | |
dc.language.iso | eng | en_US |
dc.publisher | Global Advances in Health and Medicine LLC (GAHM LLC) | en_US |
dc.rights.accessRights | openAccess | en_US |
dc.subject | VDP::Medisinske Fag: 700::Helsefag: 800::Andre helsefag: 829 | en_US |
dc.subject | VDP::Medical disciplines: 700::Health sciences: 800::Other health science disciplines: 829 | en_US |
dc.subject | Multiple sclerosis | en_US |
dc.subject | MS | en_US |
dc.subject | complementary and alternative medicine | en_US |
dc.subject | CAM | en_US |
dc.subject | case report | en_US |
dc.subject | Norway | en_US |
dc.title | A Patient-defined "Best Case" of Multiple Sclerosis Related to the Use of Complementary and Alternative Medicine | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |